Ondine Biomedical OBI.L · GBp

Its shares trade on LSE under the ticker OBI.L. It has been listed since 6 December 2021. In the fiscal year to 31 December 2025, it reported revenue of C$2.7m and a net loss of C$29.6m. At that date it held total assets of C$14.4m and shareholders' equity of C$3.5m.

Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is engaged in photodisinfection-based therapies to prevent and treat a range of infections, including those caused by drug-resistant pathogens. Its lead product, Steriwave, is a rapid nasal decolonization therapy that eradicates a broad spectrum of pathogens in the nose in only minutes. Steriwave enables rapid elimination of pathogens associated with healthcare-associated infections (HAIs), reduces the reliance on patient compliance and screening, and eliminates the generation of resistance associated with topical antibiotics and other antimicrobials. The company also has several products in development, including treatment of chronic rhinosinusitis, decolonization of burns and wounds, disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia and the development of topical antiviral therapy for the upper respiratory tract, including the reduction of SARS-CoV-2 titre and transmission.

Figures and description from our data supplier, not checked against the company's own report.

• The Hon. Jean CharestNon-Executive Independent Chairman of the BoardC$10,754
• Dr. Nicolas LoebelPresident, Chief Technology Officer, Executive Director, since 2004C$1.5m
• Ms. Carolyn CrossChief Executive Officer, Executive DirectorC$1.8m
• Mr. Alan ThomasChief Financial Officer
• Mr. William KanzSenior Vice President, Engineering and Operations
• Mr. Nikita ParkhaevVice President - Finance
• Dr. Roger AndersenVice President - Regulatory and Medical Affairs
• Mr. Jason HickokVice President - Clinical and Medical Affairs
• Ms. Dawn NguyenVice President - Quality
• Ms. Angelika VanceVice President - Corporate Communications
• Dr. Simon SinclairChief Medical Officer, since 2021C$294,034
• Ms. Elaine LeiCompany Secretary

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.